Recent Quotes (30 days)

You have no recent quotes
chg | %

Dechra Pharmaceuticals plc news

   Watch this stock
Showing stories 1 - 10 of about 81   

Articles published

DPH 1,801.00 -33.00 (-1.80%)
price chart
Dechra Pharmaceuticals PLC: Annual Results
Dechra is an international specialist veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide.
Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after ...  Motley Fool UK
Dechra Pharmaceuticals PLC, Agrees Acquisition of US-based Putney, Inc for ...
Dechra Pharmaceuticals PLC (LSE: symbol DPH) announces the conditional acquisition of the entire share capital of Putney, Inc, a leading developer of generic companion animal pharmaceuticals in the US, based in Portland, Maine.
Dechra to acquire Putney, maker of generic veterinary drugs, for $200 million  dvm360
OP animal health parent leashes $200M acquisition  Kansas City Business Journal
Dechra� Pharmaceuticals PLC Trading Update
International specialist veterinary pharmaceuticals and related products business, Dechra Pharmaceuticals PLC (Dechra or the Company) (Stock Code: Full Listing (Pharmaceuticals): DPH) issues the following unaudited Trading Update covering the half year ...
Are RhythmOne plc, Dechra Pharmaceuticals plc and Pagegroup plc 'buys' after ...
Today's update from Pagegroup (LSE: PAGE) shows that the global recruitment company endured a somewhat mixed Q2. While its performance in southern Europe and Benelux was impressive with gross profit growth of 25% and 30% respectively, ...
Dechra Pharmaceuticals plc (LSE:DPH): What are the future prospects?
Based on the latest analyst predictions Dechra Pharmaceuticals plc (LSE:DPH) is estimated to grow its earnings 155.9% over the next year.
Analysts Set Dechra Pharmaceuticals plc (DPH) Target Price at $1649.17  Stock Observer
Dechra Pharmaceuticals plc (DPH) Receives GBX 1649.17 Consensus Target Price ...  Transcript Daily
Should you be buying AstraZeneca plc, Alliance Pharma plc and Dechra ...
One of the major concerns of investors in AstraZeneca (LSE: AZN) in recent years has been its ability to pay dividends. That's because it has been subjected to a patent cliff, where a number of key drugs have come off-patent and with the company ...
Analysts Set Dechra Pharmaceuticals plc (DPH) Price Target at $1649.17
Dechra Pharmaceuticals plc logo Dechra Pharmaceuticals plc (LON:DPH) has been given an average rating of “Buy” by the eight brokerages that are presently covering the stock, MarketBeat Ratings reports.
Permal Asset Management Lowered Starwood Ppty Tr (STWD) Position By $483000 ...  Thorold News
4 Great Growth Picks For 2016 And Beyond: Barclays PLC, Dechra Pharmaceuticals ...
The world of pet healthcare is a fast-growing market, making animal medicines and specialist food producer Dechra Pharmaceuticals (LSE: DPH) a star pick in my opinion. The business saw revenues jump 5.1% during the year ending September, to �203.5m ...
Dechra Pharma Names Richard Cotton CFO Designate
Dechra Pharmaceuticals plc. (DPH.L) announced Wednesday the appointment of Richard Cotton as Chief Financial Officer. Cotton will join the Company once he has served the notice period in his current role, which is expected to be by the beginning of ...
3 Fast-Growing Pharmaceuticals Set To Outperform: Shire PLC, BTG plc and ...
Back in February last year I penned an article titled David & Goliath: AstraZeneca versus Hikma Pharmaceuticals, which compared the prospects of the two firms and suggested that looking down the food chain in the pharmaceutical sector could produce an ...